Skip to main content

Table 2 Characteristics of IPD patients by age and immunocompromised status (n = 281)

From: Invasive pneumococcal disease among adults in Japan, April 2013 to March 2015: disease characteristics and serotype distribution

 

Group 1 n = 10 (15–39 years, Nonimmunocompromised)

Group 2 n = 48 (40–64 years Nonimmunocompromised)

Group 3 n = 116 (> = 65 years, Nonimmunocompromised)

Group 4 n = 107 (> = 15 years Immunocompromised)

Variable

n/Na (%)

n/Na (%)

n/Na (%)

n/Na (%)

Female

3/10 (30)

10/48 (21)

46/116 (40)

44/107 (41)

BMI

 Normal or Healthy Weight (18.5 – 24.9)

5/7 (71)

24/42 (57)

57/95 (60)

47/97 (48)

 Overweight (25.0 and Above)

0/7 (0)

11/42 (26)

12/95 (13)

17/97 (18)

 Underweight (Below 18.5)

2/7 (29)

7/42 (17)

26/95 (27)

33/97 (34)

Smoking history

5/9 (56)

26/44 (59)

49/100 (49)

48/95 (51)

Alcohol abuse

2/9 (22)

13/43 (30)

13/103 (13)

11/95 (12)

Preceding influenza

0/4 (0)

2/34 (6)

8/83 (10)

1/66 (2)

Vaccination history of PPSV23

0/8 (0)

1/40 (3)

6/91 (7)

9/85 (11)

Comorbidities

1/10 (10)

25/48 (52)

69/116 (59)

107/107 (100)

Clinical presentation

 Bacteremia without any focus

1/10 (10)

4/48 (8)

12/116 (10)

29/107 (27)

 Meningitis

3/10 (30)

9/48 (19)

18/116 (16)

14/107 (13)

 Bacteremic pneumonia

6/10 (60)

27/48 (56)

80/116 (69)

54/107 (50)

 Othersb

0/10 (10)

8/48 (17)

6/116 (5)

10/107 (9)

Outcomec

 Fatal

0/10 (0)

6/48 (13)

18/116 (16)

31/107 (29)

Serotype

 PCV13 type

4/10 (40)

27/48 (56)

65/116 (56)

34/107 (32)

 PPSV23 type

7/10 (70)

38/48 (79)

85/116 (73)

55/107 (51)

  1. BMI Body mass index, PPSV23 23-valent pneumococcal polysaccharide vaccine
  2. a Number of available answers
  3. b Others included bacteremic arthritis, bacteremic cellulitis, bacteremic spondylitis bacteremic cholangitis, bacteremic empyema, infected aortic aneurysm and infective endocarditis
  4. c The case fatality was defined as reporting of death by the case-reporting form at the time of reporting